OncoCyte Co. (NYSEAMERICAN:OCX) was the recipient of a significant increase in short interest in November. As of November 30th, there was short interest totalling 330,835 shares, an increase of 58.5% from the November 15th total of 208,771 shares. Approximately 4.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 39,702 shares, the days-to-cover ratio is presently 8.3 days.

OncoCyte (NYSEAMERICAN:OCX) traded down $0.05 on Monday, reaching $5.15. The company’s stock had a trading volume of 5,535 shares, compared to its average volume of 27,669. OncoCyte has a one year low of $3.60 and a one year high of $7.95.

An institutional investor recently raised its position in OncoCyte stock. Broadwood Capital Inc. boosted its position in shares of OncoCyte Co. (NYSEAMERICAN:OCX) by 17.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,596,680 shares of the biotechnology company’s stock after purchasing an additional 540,000 shares during the quarter. OncoCyte makes up 4.5% of Broadwood Capital Inc.’s portfolio, making the stock its 5th biggest holding. Broadwood Capital Inc. owned 11.48% of OncoCyte worth $27,155,000 at the end of the most recent quarter.

OCX has been the topic of a number of analyst reports. Zacks Investment Research downgraded OncoCyte from a “hold” rating to a “sell” rating in a research note on Saturday, November 18th. ValuEngine downgraded OncoCyte from a “hold” rating to a “sell” rating in a research note on Thursday, October 5th.

TRADEMARK VIOLATION WARNING: “OncoCyte Co. (OCX) Short Interest Up 58.5% in November” was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/11/oncocyte-co-ocx-short-interest-up-58-5-in-november.html.

OncoCyte Company Profile

OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment.

Receive News & Ratings for OncoCyte Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte Co. and related companies with MarketBeat.com's FREE daily email newsletter.